ArticleLeukemia & lymphoma2021
Clinical characteristics and outcomes of black patients with mycosis fungoides and Sézary syndrome: a subgroup analysis of the phase III MAVORIC trial.
Article in Leukemia & lymphoma, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Persistent racial and socioeconomic inequities in mycosis fungoides survival: a population-based study.Frontiers in public health · 2026Article
- The Evaluation of Skin Infiltration in Mycosis Fungoides/Sézary Syndrome Using the High-Frequency Ultrasonography.Journal of clinical medicine · 2025Article
- Pharmacovigilance study for the identification of mogamulizumab-induced immune-related adverse events using a real-world database.The oncologist · 2025Article
- Concurrent papular and dyshidrotic mycosis fungoides: A case report in a patient with skin of color.JAAD case reports · 2024Article
- Racial Disparities in Mycosis Fungoides/Sézary Syndrome-A Single-Center Observational Study of 292 Patients.Clinical lymphoma, myeloma & leukemia · 2024Observational
- Clinical and Real-World Effectiveness of Mogamulizumab: A Narrative Review.International journal of molecular sciences · 2024Review
- Blockade of the Immune Checkpoint CD47 by TTI-621 Potentiates the Response to Anti-PD-L1 in Cutaneous T-Cell Lymphoma.The Journal of investigative dermatology · 2023Article
- Mycosis fungoides and Sézary syndrome.Blood research · 2023Review
- Cutaneous T-cell lymphomas: 2023 update on diagnosis, risk-stratification, and management.American journal of hematology · 2023Article
- African American and Caucasian patients with Sézary syndrome have no differences in outcomes at an ethnically diverse urban medical center.Leukemia & lymphoma · 2022Article
- Cutaneous T-cell lymphomas: 2021 update on diagnosis, risk-stratification, and management.American journal of hematology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Treatment-specific responses and comprehensive disease characteristics are limited in black patients with cutaneous T-cell lymphoma (CTCL). These shortcomings prompted us to perform a subgroup analysis of black patients enrolled in the MAVORIC trial - an international, randomized, phase 3 trial comparing mogamulizumab vs. vorinostat in relapsed/refractory mycosis fungoides (MF) and Sézary syndrome (SS). Ten percent (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.